Duchenne News Tags: Astellas Pharma

November 16, 2023

Astellas Study Results Available for ASP0367 (MA-0211) in Pediatric Male Patients with Duchenne Muscular Dystrophy

Astellas shares a Community Letter with information on results for ASP0367 for treatment of Duchenne.

Astellas Discontinues Further Screening and Enrollment for ASP0367 (MA-0211) in Pediatric Male Patients with Duchenne

Astellas discontinues screening and enrollment for ASP0367

Astellas Announces Opening of Phase 1b Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ASP0367

On Sept. 1, 2022, Astellas announced that their Phase 1b study is now open at sites across the United States. They will be adding more sites as they become ready...

Support Jett Foundation

Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Programs

Events